Xencor XNCR 深 沪
已收盘 07-10 16:00:00 美东时间
15.85
-0.265
-1.64%
华盛通- 最 高15.89
- 今 开15.84
- 成交量 54.47万股
- 最 低 15.11
- 昨 收 16.115
- 总市值 11.75亿
- 52周最高 18.69
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 6.92
- 委 比 -90.23%
- 总股本 7414.16万
- 历史最高 58.345
- 量 比 0.57
- 振 幅 4.84%
- 历史最低 5.75
- 每 手 1
- 风险率 2.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Truist Securities Maintains Buy on Xencor, Lowers Price Target to $27
Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the price target from $29 to $27.
07-07 20:29
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Incyte’s (INCY) immunotherapy Monjuvi, developed with Xencor (XNCR), will soon become a first-line option for a common type of lymphoma after late-stage trial data indicated on Saturday that the CD19-...
05-31 01:46
MindWalk publishes Discovery-to-Clinic presentation factsheet
MindWalk publishes Discovery-to-Clinic presentation factsheet MindWalk Holdings published a Discovery-to-Clinic presentation detailing more than 20 partner-owned drug candidates originating from its antibody discovery work, including 10 programs in active Phase 1-3 clinical trials. Highlighted clini
05-18 20:36
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
This SAP Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.
03-25 00:02
JP Morgan Downgrades Xencor to Neutral, Lowers Price Target to $13
JP Morgan analyst Brian Cheng downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowers the price target from $18 to $13.
03-24 20:08
Xencor, Genentech to End Protein Therapeutics Collaboration
Xencor ( ($XNCR) ) just unveiled an update. Xencor, Inc., a biopharmaceutical d...
03-10 04:46
Xencor shares are trading lower after Alexion Pharmaceuticals informed the company it does not owe additional royalties for Ultomiris sales in the U.S.
Xencor shares are trading lower after Alexion Pharmaceuticals informed the comp...
03-06 01:02
